Non-alcoholic fatty liver disease in Poland : how and at what stage is diagnosed, and how is treated : a survey study by Ciećko-Michalska, Irena et al.
Original paper
Non-alcoholic fatty liver disease in Poland: how 
and at what stage is diagnosed, and how is treated. 
A survey study
Irena Ciećko-Michalska1, Małgorzata Szczepanek2, Beata Tobiasz-Adamczyk3, Tomasz Mach1
1Department of Gastroenterology, Hepatology, and Infectious Diseases, Jagiellonian University Medical College, Krakow, Poland 
2Department of Medical Didactics, Jagiellonian University Medical College, Krakow, Poland 
3hair of Epidemiology and Preventive Medicine, Jagiellonian University Medical College, Krakow, Poland
Gastroenterology Rev 2019; 14 (3): 173–177
DOI: https://doi.org/10.5114/pg.2019.88165
Key words: non-alcoholic fatty liver disease, survey study, diagnosis, treatment.
Address for correspondence: Ass. Prof. Irena Ciećko-Michalska, Department of Gastroenterology, Hepatology, and Infectious Diseases, 
Jagiellonian University Medical College, 5 Śniadeckich St, 31-531 Krakow, Poland, phone: +48 12 424 73 82, e-mail: i.ciecko-michalska@
uj.edu.pl, michalska@su.krakow.pl
Abstract
Introduction: Epidemiological studies show an increasing incidence of overweight and obesity all over the world, leading to 
an increase in the number of patients consulted due to liver damage. 
Aim: Assesement to which doctors (general practitioners or specialist) refer patients with elevated liver enzymes in Poland, 
how they are diagnosed and treated.
Material and methods: We conducted questionnaire surveys among 1322 doctors of various specialties to find the most 
common causes of liver disease, at which stage of the disease patients reported to doctors, and what schemes of management 
are followed.
Results: Non-alcoholic fatty liver disease (NAFLD) was the most common cause of abnormal liver enzymes (59.7%). Patients 
with liver damage most often reported to internal medicine specialists (59%) and gastroenterologists (27.5%). The diagnosis 
was based on abnormal aminotransferases (80.8%) and abdominal ultrasound examination (89.9%). Computed tomography/
magnetic resonance imaging (50.2%) and liver biopsy (22.4%) were used to assess fibrosis. Almost all respondents recommended 
reduction of body mass and lifestyle changes, and less than half (46.4%) recommended pharmacological treatment.
Conclusions: NAFLD was the most common liver disease that was the reason for medical consultations, but its incidence 
seems to be underestimated due to referral for further diagnostics only in patients with abnormal aminotransferases. The 
diagnostic methods used to assess the severity of the liver fibrosis and the recommended pharmacological treatment varied 
depending on the physician’s specialisation and the centre’s reference level.
Introduction
The results of studies indicate a worldwide in-
creasing incidence of non-alcoholic fatty liver disease 
(NAFLD), with the highest prevalence exceeding 25% in 
the Middle East and South America, and the lowest in 
Africa [1]. Most often, NAFLD is associated with obesi-
ty, diabetes type 2, and metabolic syndrome [1, 2], but 
also affects about 7% of lean people [3]. Cohort studies 
in a large group of patients revealed that NAFLD can 
develop in overweight and obese people without met-
abolic disorders, which may suggest that the obesity 
itself increase the risk of NAFLD [4]. NAFLD is twice as 
frequent in men as in women [5]. NAFLD is an important 
factor in the development of liver cirrhosis and hepato-
cellular carcinoma (HCC) – indications for liver trans-
plantation [6]. 
Liver biopsy is the only method that enables the 
differentiation of non-alcoholic fatty liver (NAFL) from 
non-alcoholic steatohepatitis (NASH), because neither 
clinical evaluation nor biochemical tests allow unequiv-
ocal exclusion of NASH, which may result in progressive 
fibrosis, cirrhosis, or HCC [7].
Significant obesity increases the risk of NASH and 
intensity of fibrosis from 10% to 30% [8].
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American prognosis estimates an increase in the 
overall prevalence of NAFLD by 2030 to 33.5%, an in-
crease in the number patients with NASH from 20% to 
27%, an increase of 168% in the number of patients with 
end-stage liver cirrhosis, an increase of 137% in the num-
ber of patients with NAFLD-derived HCC, and a 178% in-
crease in the number of hepatic-related deaths [9].
We decided to perform this study to check which 
doctors (general practitioners or specialist) patients 
with elevated liver enzymes are referred to in Poland, 
and how they are diagnosed and treated.
Aim
We wanted to assess what, in the opinion of doc-
tors, is the most common cause of liver damage and at 
what stage of the disease patients report to the doc-
tor, how they are diagnosed and treated in Poland, and 
whether it is related to the doctors’ specialisation and 
place of work.
Material and methods
In cooperation with the Chair of Epidemiology and 
Preventive Medicine of the Jagiellonian University, we 
prepared a questionnaire containing 12 questions 
(some of them with multiple answers). The approval of 
the Bioethical Committee of the Jagiellonian University 
was obtained to carry out the study. 
Questionnaires were collected by interviewers from 
the doctors who agreed to participate.
The questionnaire survey involved 1322 physicians, 
specialists in family medicine, internal medicine, gastro-
enterology, infectious diseases, cardiology, and diabetol-
ogy working in primary health care, specialistic outpa-
tient clinics, hospitals and clinical wards, and diagnostic 
laboratories. The average age of the respondents was 
almost 34 years (mean age 33.926 years).
Statistical analysis
The statistical analysis of the obtained responses 
was made using the IBM SPSS Statistics 25 package. 
In order to check if there were statistically significant 
differences between two independent groups, the 
Mann-Whitney U test was used.
Analysis using the c2 test allowed us to check 
whether the compared groups were the same size, as 
well as whether there was a statistically significant rela-
tionship between the nominal variables (g2). The p-value 
< 0.05 was considered statistically significant.
Results
Among the respondents, the largest group com-
prised specialists in internal medicine (n = 780, 59%) 
and gastroenterologists (n = 363, 27.5%) working in 
hospital wards (n = 780, 59%) and specialist outpatient 
clinics (n = 418, 31.6%).  
Significantly more physicians wrote that the most fre-
quent cause of abnormal liver enzymes among patients 
reporting to them was NAFLD, g2(1) = 49.57, p < 0.001 
and alcoholic liver disease, g2 (1) = 38.63, p < 0.001. 
Analysis using the U Mann-Whitney test showed 
that the average age of doctors who consulted weekly 
1–5 patients with NAFLD was statistically significant-
ly lower (mean ± SD: 43.98 ±11.97) compared to doc-
tors who consulted larger number of patients (47.16 
±25.17), p < 0.05.
Significantly more respondents concluded that 
NAFLD affects patients aged from 31 to 50 years 
(57.5%, g2(1) = 29.65, p < 0.001) and from 51 to 70 
years (42.1%).
The respondents gave ambiguous answers concern-
ing who is more often affected by fatty liver: 44.8% of 
respondents stated that in their opinion liver steatosis 
affects mainly men, and 41.1% reported that it is equal-
ly common in men and women.
The majority of the surveyed doctors stated that 
among patients diagnosed by them NAFLD was most of-
ten accompanied by: obesity, g2(1) = 936.78, p < 0.001; 
lipid disorders, g2(1) = 476.88, p < 0.001; and type 2 dia-
betes, g2(1) = 345.67, p < 0.001 (Table I). Over three-quar-
ters of respondents stated that patients with NAFLD 
most often refer to the doctor at the stage of non-alco-
holic fatty liver (NAFL), g2(1) = 392.13, p < 0.001.
Respondents stated that they mainly based NAFLD 
diagnoses in their patients on: abdominal ultrasound 
examination, g2(1) = 842.56, p < 0.001; liver enzymes 
activity analyses, g2(1) = 501.21, p < 0.001; or  anamne-
sis and physical examination, g2(1) = 29.65, p < 0.001. 
In the diagnostics of fibrosis advancement, respondents 
primarily recommended imaging examinations: com-
puted tomography (CT) and magnetic resonance imag-
ing (MRI) as well as liver biopsy, and far less frequently 
FibroScan and elastography (Table II).
The c2 analysis did not reveal any statistically sig-
nificant relationships between the specialty or the 
Table I. Therapeutic recommendations received by 
patients with NAFLD
Recommendations for patients diagnosed 
with NAFLD
N %
Body mass reduction 1236 93.5
Increased physical activity 1101 83.3
Introduction of a low-fat diet 1091 82.5
No recommendations 12 0.9
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workplace of respondents and the type of procedures 
ordered to diagnose or evaluate the advancement of 
liver damage in patients with NAFLD.
Non-invasive tests (SteatoTest, NashTest, FibroTest, 
cytokeratin 18 concentration) are ordered primarily 
by infectious disease specialists and diabetologists, 
g2(5) = 45.02, p < 0.001. Liver biopsy is ordered pri-
marily by infectious diseases specialists, g2(5) = 37.52, 
p < 0.001.
Analysis of the type of diagnostic tests recommend-
ed to assess fibrosis depending on the physician’s spe-
cialisation and workplace showed that: FibroTest is 
ordered primarily by gastroenterologists and infectious 
disease specialists, g2(5) = 12.06, p < 0.05, working in 
a specialist outpatients clinic, g2(4) = 13.95, p < 0.01. 
Similarly, FibroScan, g2(5) = 147.02, p < 0.05 is ordered 
primarily by doctors with a specialisation in infectious 
diseases and gastroenterology working in a specialist 
outpatient clinic, g2(4) = 54.32, p < 0.001. In contrast, 
elastography is ordered by gastroenterologists and in-
fectious disease specialists, g2(5) = 78.84, p < 0.001, 
working in a clinical ward; g2(4) = 32.84, p < 0.01.
CT/ MR is ordered by cardiologists, diabetologists, 
and specialists in internal medicine, g2(5) = 18.79, 
p < 0.01, working in a clinical ward and diagnostic lab-
oratory, g2(4) = 15.41, p < 0.01. 
Liver biopsy in patients with NAFLD for the diag-
nosis of the disease, assessment of fibrosis stage, and 
exclusion of other causes of liver damage was ordered 
primarily by specialists in infectious diseases and gas-
troenterology, g2(5) = 56.92, p < 0.05, working in a clin-
ical ward or specialistic outpatient clinic, g2(4) = 31.27, 
p < 0.001. 
Regarding in the treatment, the majority of the sur-
veyed doctors recommended the following to their pa-
tients with NAFLD: weight reduction, g2(1) = 1000.38, 
p < 0.001; increase in physical activity, g2(1) = 585.78, 
p < 0.001; and introduction of a low-fat diet without 
simple sugars, g2(1) = 559.45, p < 0.001 (Table I).
Among the various forms of pharmacological treat-
ment, fewer than half of the respondents indicated the 
following: statins, essential phospholipids (EPL), and 
ursodeoxycholic acid (UDCA) (Table III).
Discussion
The results of our study show that NAFLD is the 
most common liver disease leading to medical consul-
tations in Poland. In most cases, patients are less than 
50 years old, in a smaller percentage between 51–70 
years, and over three-quarters are patients with fatty 
liver.
In the Framingham Heart Study, in people with 
fatty liver (after the exclusion of people who abused 
alcohol – “heavy alcohol users”) without known liver 
disease, higher mean serum levels of systemic markers 
of inflammation were found [10]. This would suggest 
that hepatic steatosis should be treated, and that re-
ducing the inflammation might reduce the progression 
to NASH and subsequent stages of the disease and 
its complications. If treatment is not started, it is to 
be expected that in a dozen or so years the American 
prognosis [9] may also come true in other countries. 
The high prevalence of NAFLD in patients with type 2 
diabetes underlines the need for early assessment of 
NAFLD in this group of patients [11].
A meta-analysis of 8,515,431 patients showed that 
obesity, dyslipidaemia (especially hypertriglyceridae-
mia), and diabetes were more frequently diagnosed in 
patients with NASH [1]. In a study of 432 patients with 
histologically confirmed NAFLD (26.8% NASH, 17.4% 
with moderate to severe fibrosis), diabetes and activity 
of aminotransferases proved to be independent prog-
nostic factors of moderate to severe fibrosis and can 
be used to identify patients with NAFLD at risk of ad-
vanced fibrosis [12].
Table II. Recommended diagnostic tests enabling the 
assessment of the severity of liver fibrosis
Recommended diagnostic tests to assess 
the severity of liver fibrosis
N %
Non-invasive tests, e.g. FibroTest 149 11.3
Calculators, e.g. FIB-4, or NAFLD fibrosis score 76 5.7
FibroScan 275 20.8
Elastography 267 20.2
Other imaging studies: CT/MRI 664 50.2
Liver biopsy 296 22.4
Table III. Pharmacotherapy recommended to patients 
with NAFLD
Pharmacotherapy recommended to 
patients with NAFLD
N %
Statins 614 46.4
Essential phospholipids (EPL) 645 48.8
Ursodeoxycholic acid (UDCA) 633 47.9
Vitamin E 342 25.9
ω-3 fatty acids 222 16.8
Thiazolidinediones 50 3.8
Others, e.g. milk thistle extract, L-ornithine 
L-aspartate, thiazolidine carboxylic acid 
655 49.5
I do not recommend any drugs 121 9.2
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The results of our study indicated the important role 
of anamnesis, which often rules out toxic aetiology, in-
cluding alcohol and other causes of chronic liver diseases.
It was also shown that the NAFLD diagnosis in the 
majority of cases was based on liver enzyme activity 
and abdominal ultrasound; non-invasive biochemical 
tests such as: SteatoTest, ActiTest, NashTest, or cytoker-
atin 18 were used less frequently, mainly by infectious 
disease specialists or diabetologists. This demands re-
flection, because the results of studies indicate that for 
the patients with NAFLD these tests are an alternative 
to liver biopsy [13].
In a survey study conducted among French gastro-
enterologists, non-invasive markers of fibrosis were 
used by 90% of respondents [14].
Liver biopsy is currently the most reliable test for 
NASH or liver fibrosis evaluation in patients with NAFLD, 
while aminotransferases activity, liver ultrasound, or 
other imaging tests such as computed tomography (CT) 
or magnetic resonance (MRI), do not accurately reflect 
the spectrum of histological changes in the liver [1]. In 
our study we found that liver biopsy was recommended 
in more than one fifth of NAFLD patients by infectious 
disease specialists and gastroenterologists to assess 
the severity of fibrosis.
A liver biopsy is not recommended as a screening 
test for NAFLD in a healthy population, nor is it rec-
ommended for asymptomatic patients with fatty liver 
in abdominal ultrasound examination, without signif-
icant risk factors for metabolic syndrome and insulin 
resistance. The indication for liver biopsy is a lack of 
biochemical improvement despite adherence to ther-
apeutic recommendations, and abnormal results of 
non-invasive tests indicating liver fibrosis [15]. 
According to the current guidelines [1], the respon-
dents recommended that their patients adopt a low-cal-
orie low-fat diet, increase physical activity, and reduce 
body mass. 
In our study, in addition to the change of lifestyle, 
specialists in outpatient clinics recommended statins 
and UDCA to almost half of the patients, while primary 
care physicians recommended that more than 50% of 
their patients use essential phospholipids (EPL), milk 
thistle extract, L-ornithine L-aspartate, and thiazolidine 
carboxylic acid. Pioglitazone was the most commonly 
prescribed drug among the drugs that increase insulin 
sensitivity.
NAFLD treatment is mainly based on the treatment 
of metabolic disorders, additionally supported by UDCA, 
the inclusion of which resulted in the reduction of liver 
enzymes. In a study by Ratziu et al. UDCA in a dose 
28–35 mg/kg/day proved to be safe and well tolerated, 
and durably reduced the activity of alanine aminotrans-
ferase (ALT) as well as the severity of liver fibrosis, had 
a beneficial effect on glycaemic control, and improved 
insulin sensitivity [16].
In summary, it should be emphasised that patients 
with NAFLD visit doctors of various specialties, due to 
the wide spectrum of disorders accompanying this dis-
ease. 
The limitation of this study is the inability to anal-
yse data from medical records, instead using only the 
answers given by doctors. 
The study revealed that many doctors prescribed 
pharmacotherapy not recommended in the treatment 
of NAFLD, which indicates the need to train doctors in 
the recommended treatment of this disease.
Conclusions
NAFLD was the most common liver disease that was 
the reason for medical consultations due to liver en-
zyme abnormalities and fatty liver in ultrasonography, 
but its incidence seems to be underestimated due to 
referral for further diagnosis only patients with abnor-
mal aminotransferases.
The diagnostic methods used to assess the severity 
of liver fibrosis and the recommended pharmacological 
treatment varied depending on the doctors’ specialisa-
tion and the type of medical centre (hospital or outpa-
tient clinic) where they worked.
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